Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Metabolic reprogramming in KRAS-mutant cancers: Proven targetable vulnerabilities and potential therapeutic strategies.

Drug discovery today - 1 Dec 2024

Wu Ruilin, Zhu Hong, He Qiaojun, Yuan Tao, Yang Bo

Abstract excerpt

Kras (Ki-ras2 Kirsten rat sarcoma viral oncogene homolog), one of the most frequently mutated oncogenes in the human genome, is considered 'untargetable'. Although specific KRASG12C inhibitors have been developed, their overall impact is limited, highlighting the need for further research on targeting KRAS-mutant cancers. Metabolic abnormalities are key hallmarks of cancer, with KRAS-driven tumors exhibiting...

Topics

Humans
Neoplasms
Animals
Proto-Oncogene Proteins p21(ras)
Mutation
Tumor Microenvironment
Antineoplastic Agents
Molecular Targeted Therapy
Glycolysis
Metabolic Reprogramming

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39481592
DOI: 10.1016/j.drudis.2024.104220

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metabolic reprogramming in KRAS-mutant cancers: Proven targetable vulnerabilities and potential therapeutic strategies.PMID 39481592Read ↗

Targeting KRAS: from metabolic regulation to cancer treatmentSemantic proximity Read ↗

Lipid Metabolic Alterations in KRAS Mutant Tumors: Unmasking New Vulnerabilities for Cancer Therapy.Semantic proximity Read ↗

Targeting metabolic reprogramming in KRAS-driven cancers.Semantic proximity Read ↗

Rerouting the drug response: Overcoming metabolic adaptation in KRAS-mutant cancers.Semantic proximity Read ↗

The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?Semantic proximity Read ↗

Metabolic reprogramming by driver mutation-tumor microenvironment interplay in pancreatic cancer: new therapeutic targets.Semantic proximity Read ↗

Oncogenic KRAS triggers metabolic reprogramming in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Metabolic rewiring in mutant Kras lung cancer.Semantic proximity Read ↗

Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets.Semantic proximity Read ↗

Targeting cancer's metabolic co-dependencies: A landscape shaped by genotype and tissue context.Semantic proximity Read ↗

The complex landscape of pancreatic cancer metabolismSemantic proximity Read ↗

Metabolic reprogramming of carcinoma-associated fibroblasts and its impact on metabolic heterogeneity of tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.